Advertisement
open access
Medical Conferences
Conference Reports
Conference Proceedings
Other Medical News
Multimedia
Podcast Channel
Videos
Webinar
About
2024 Medicom Conference Planning
Conference Proceedings-3
Home
>
Dermatology
>
AAD 2024
AAD 2024
American Academy of Dermatology
08–12
March 2024 San Diego, USA
Table of Contents
Colophon
Table of Contents
Featured articles
Letter from the Editor
Presented By
Prof. Peter van de Kerkhof, Radboudumc, the Netherlands
Meet the Trialist: Dr Andrew Blauvelt on the KNOCKOUT Trial
Expert
Dr Andrew Blauvelt
AAD 2024 Highlights Podcast
Presented By
Robert van den Heuvel, Medicom
New Developments in Dermatology
Upadacitinib: A novel treatment option for vitiligo
Presented By
Prof. Thierry Passeron, Nice University Hospital, France
JAK1 inhibitor meets primary endpoint in prurigo nodularis
Presented By
Prof. Martin Metz, Charité University Hospital, Germany
Botanical drug solution leads to sustained hair regrowth in paediatric alopecia
Presented By
Prof. Bianca Piraccini, University of Bologna, Italy
SGLT2 inhibition: A possible mode-of-action for inflammatory skin diseases?
Presented By
Allison Holt, UMass Chan Medical School, USA
Promising first results of novel topical treatment for congenital ichthyosis
Presented By
Dr Christopher Bunick, Yale School of Medicine, USA
Ritlecitinib also effective in patients with total hair loss
Presented By
Dr Melissa Piliang, Cleveland Clinic, USA
Atopic Dermatitis and Eczema in 2024
Amlitelimab leads to a high response 28 weeks after treatment discontinuation
Presented By
Prof. Stephan Weidinger, Christian-Albrechts-University Kiel, Germany
Delgocitinib cream: A promising treatment option for chronic hand eczema
Presented By
Prof. Melinda Gooderham, Queens University, Canada
The Latest in Psoriasis
Robust long-term efficacy of bimekizumab in psoriasis
Presented By
Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA
Benefit and safety of TYK2 inhibitor ESK-001 for psoriasis in phase 2
Presented By
Dr Kim Papp, Probity Medical Research, Canada
Durable skin clearance by IL-23 blockers due to reduction of resident memory T cells
Presented By
Prof. Andrew Blauvelt, Oregon Medical Research Center, USA
Hidradenitis Suppurativa: New Treatment Possibilities
HS: Targeting IL-1 pathway potential option after anti-TNF failure
Presented By
Prof. Falk Bechara, Ruhr-University Bochum, Germany
BTK signalling as a novel target in hidradenitis suppurativa treatment
Presented By
Prof. Alexandra Kimball, Harvard Medical School, USA
Topical ruxolitinib shows promise in milder stages of hidradenitis suppurativa
Presented By
Prof. Martina Porter, Beth Israel Deaconess Medical Center, MA, USA
Best of the Posters
Children with atopic dermatitis may be smaller and heavier than healthy children
Presented By
Prof. Amy Paller, Northwestern University‘s Feinberg School of Medicine, USA
JAK inhibitors have similar incidence rates of long-term adverse events as traditional immunomodulators
Presented By
Olivia Lamberg, University of Michigan, USA
Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years
Presented By
Prof. Maryanne Senna, Harvard Medical School, USA
GUIDE demonstrates: Hit hard and early in psoriasis
Presented By
Prof. Knut Schäkel, University Clinic Heidelberg, Germany
Hidradenitis suppurativa treatment with secukinumab linked to low immunogenicity
Presented By
Prof. Martina Porter, Beth Israel Deaconess Medical Center, USA